Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Eliminating hepatitis

Hepatitis awareness

Friday 28 July marks the World Health Organization's (WHO) World Hepatitis Day — an opportunity "to add momentum to all efforts to all efforts to implement the WHO's global health sector strategy on hepatitis for 2016–2021 and help countries achieve the final goal — to eliminate hepatitis." Read The Pharmaceutical Journal's on tackling this group of diseases.

Transmission Electron Micrograph view (TEM) of Hepatitis B virus

An update on the management of chronic hepatitis B and C infectionSubscription

By , , , ,

Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to ...

Marc Bulterys, team leader of the global hepatitis programme (GHP) at the World Health Organization (WHO)

World Health Organization looks to eliminate threat of hepatitis B and CSubscription

By

The World Health Organization’s Marc Bulterys on the agency’s efforts to eliminate viral hepatitis by scaling up screening and improving access to new and effective drugs

Micrograph of cirrhosis of the liver

Statins benefit patients with hepatitis B and C-related cirrhosis

Statins may benefit patients with cirrhosis of the liver caused by the Hepatitis B (HBV) or Hepatitis C (HCV) virus, according to the results of a Taiwan study published in Hepatology[1] (online, 20 March 2017).

Winners of the 2015 Care Awards Audience Choice Awards. From left, Ryan Buchanan, Pembe Hassan-Hicks and Kevin Noble

Community pharmacy helps diagnose people with hepatitis C infection, study shows

By

Community pharmacists have the potential to identify people with undiagnosed hepatitis C infection, according to research published in Clinical Pharmacist.

Close-up of a person taking a dry-blood spot test

Integrating community pharmacy testing for hepatitis C with specialist careSubscription

By Ryan Buchanan, Pembe Hassan-Hicks, Kevin Noble, Leonie Grellier, Julie Parkes, Salim I Khakoo

Many patients with hepatitis C virus (HCV) infection lie undiagnosed and a significant proportion of patients that have been identified are disengaged from specialist services. The Isle of Wight (IOW) typifies this issue, with an estimated 200 undiagnosed patients with HCV infection and a small number of known cases engaged with specialist services. Aim: To reduce the burden of undiagnosed HCV on the IOW and link new diagnoses directly ...

Liver cancer

EMA extends review of antivirals for hepatitis CSubscription

The European Medicines Agency is extending its review of direct-acting antiviral treatments for hepatitis C to look at evidence that shows they are associated with liver cancer recurrence.

European Medicines Agency headquarters

EMA to review safety of direct-acting antivirals after reports of hepatitis B reactivationSubscription

The European Medicines Agency is to review the safety of direct-acting antivirals used to treat patients with chronic hepatitis C infection.

Targeting Hepatitis C: How new treatments work

Targeting hepatitis C — how new treatments workSubscription

By

There are >185 million people with hepatitis C infection worldwide but new treatments mean that most people with access to therapy can now be cured. 

More on hepatitis

Transmission Electron Micrograph view (TEM) of Hepatitis B virus

An update on the management of chronic hepatitis B and C infectionSubscription

By , , , ,

Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to ...

Marc Bulterys, team leader of the global hepatitis programme (GHP) at the World Health Organization (WHO)

World Health Organization looks to eliminate threat of hepatitis B and CSubscription

By

The World Health Organization’s Marc Bulterys on the agency’s efforts to eliminate viral hepatitis by scaling up screening and improving access to new and effective drugs

Hepatitis C virions

Direct-acting antivirals successfully treating hepatitis C, says Public Health England

Public Health England is urging the public to get tested for hepatitis C after its latest figures revealed a fall in deaths from the disease, which it attributed to the introduction of direct-acting antiviral therapy.

combined sofosbuvir treatment for hepatitis C

Combination treatment for hepatitis C approved by FDA

The US Food and Drug Administration (FDA) has approved the use of the combination treatment Vosevi (sofosbuvir, velpatasvir and voxilaprevir) for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1–6 without cirrhosis or with mild cirrhosis.

Liver transplant, operating room

Antiviral treatment improves outcomes in patients with advanced cirrhosisSubscription

Hepatitis C drug shown to reduce the need for transplant and lower mortality rate in patients with advanced liver disease.

hepatitis c virus test

Cochrane study on direct-acting antivirals is 'fundamentally flawed', says Hepatitis C Trust

The Hepatitis C Trust has criticised a study carried out by the Cochrane Hepato-Biliary Group that cast doubt on the effectiveness of direct-acting antivirals against hepatitis C, saying it is “fundamentally flawed”.

slide showing healthy liver tissue vs cirrhotic liver tissue

Study finds no evidence for clinical effect of direct-acting antivirals against hepatitis C

Direct-acting antivirals for chronic hepatitis C, do not seem to reduce the risk of hepatitis C-related morbidity or all-cause mortality, according to a study carried out by the Cochrane Hepato-Biliary Group.

Micrograph of cirrhosis of the liver

Statins benefit patients with hepatitis B and C-related cirrhosis

Statins may benefit patients with cirrhosis of the liver caused by the Hepatitis B (HBV) or Hepatitis C (HCV) virus, according to the results of a Taiwan study published in Hepatology[1] (online, 20 March 2017).

The US Food and Drug Administration (FDA)

FDA approves first direct-acting antivirals for adolescents with hepatitis C

The US Food and Drug Administration (FDA) has approved Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) for the treatment of hepatitis C in adolescents aged 12–17 years.

Medicines on shelf

Global spend on medicines to reach US$1.5 trillion by 2020, analysts project

The global spend on medicines is predicted to reach US$1.5 trillion by 2020 — a rise of 33% from 2016 figures, according to a financial forecast by the QuintilesIMS Institute.

More on hepatitis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

Pharmaceutical Journal Jobs

More jobs